Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
News|Articles|December 17, 2021
- Pharmaceutical Technology's In the Lab eNewsletter, January 2022
- Volume 17
- Issue 1
Asahi Kasei Medical Acquires Bionique
Author(s)Pharmaceutical Technology Editors
Bionique Testing Laboratories has been acquired by Asahi Kasei Medical and will join the company’s biosafety testing services unit.
Advertisement
Bionique Testing Laboratories, a provider of mycoplasma testing services, has been 100% acquired by a subsidiary of the Japan-based healthcare company, Asahi Kasei Medical. With the acquisition, Bionique will be joined with ViruSure, an Austria-based viral and prion safety testing services company, which is a part of the global biosafety testing services unit of Asahi Kasei Medical’s Bioprocess Division. Both Bionique and ViruSure will continue operations under their existing brands, which Bionique announced in a Dec. 15, 2021 press release.
The acquisition combines Bionique’s mycoplasma and viral safety capabilities with ViruSure’s expertise, expanding Asahi Kasei Medical’s biosafety testing services. Asahi Kasei Medical is also actively investing in facility and employment expansion at various operating sites of both Bionique and ViruSure, according to the press release.
“Joining the Asahi Kasei group will enable Bionique to consolidate its leadership position in the global mycoplasma testing arena and afford our clients access to ViruSure’s service portfolio, satisfying their end-to-end biosafety testing needs from discovery through commercialization,” said Gladis Zamparo, CEO of Bionique, in the press release.
“We are excited to have a strategic partner like Bionique as part of the Asahi Kasei group, and
the expertise in mycoplasma testing that they bring will further strengthen our goal to better
service our customers in all areas of biosafety testing,” said Andy Bailey, CEO of ViruSure, in the press release.
Source:
Articles in this issue
almost 5 years ago
Without a Particle of Doubtalmost 5 years ago
Automation Helps Streamline Glycosylation Monitoring Workflowalmost 5 years ago
Advancing Enzyme Analysis Through Automationalmost 5 years ago
New High Fidelity CRISPR Cas9 Protein Reduces Off-Target Effectsalmost 5 years ago
Amgen Extends Collaboration with Syngene InternationalAdvertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement